Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded with the volume of 13.94 Million Yesterday. The Stock Opened its session at $23.77 and closed at $23.16 by showing an decrease of -2.2 percent. Valeant Pharmaceuticals International, Inc. has 1 year price target of 43.63. The stock gained a consensus recommendation of 2.66 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The company is expected to report its next EPS (earnings per share) on Nov 08 BMO.  The company reported its last quarter on Jun 16.

On Jun 16 Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported its EPS in the last quarter as $1.4/Share lagging the analyst estimate of $1.47/Share by the difference of $-0.07. This showed the surprise of -4.8% in the last quarter earnings. For the Current Quarter, 7 analyst are projecting the mean EPS to be $1.67/share. According to their observations and findings, the stock could provide a high EPS of $1.94/share and a Low EPS of $1.47/share.

The 19 analysts offering 12-month price forecasts for Valeant Pharmaceuticals have a median target of 35.00, with a high estimate of 81.00 and a low estimate of 16.00. The median estimate represents a +51.12% increase from the last price of 23.16. (CNN MONEY)

Many Analysts provided their foresight on Revenue Estimates of Valeant Pharmaceuticals International, Inc. where they believe that the company has the potential to earn average revenue of $2.5 Billion for the current quarter. According to their predictions High & Low revenue estimates are 2.55 Billion and 2.42 Billion respectively.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) topped its 52-week high price of $179.83 on Oct 16, 2015 and 52-Week Low Price of $18.55 on Jun 27, 2016. The Stock currently has the market capitalization of $8.08 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 4.35%% and monthly volatility of 4.05%% respectively.

Valeant Pharmaceuticals International, Inc. is currently showing -35.7% EPS growth this year. The Next Year EPS growth is 17.9%, Long term annual growth estimate of 11.07%, Annual EPS growth past 5 years of 24.31 percent. The Company currently has Insider ownership of 2.3 Percent and Institutional Ownership of 66.8 Percent. The Return on Assets stands at -2%, Return on Equity shows -17% and Return on Investment value is 3.7%.

Valeant Pharmaceuticals International, Inc. Gross Margin percentage stands at 74.7% while its Operating Margin for trailing twelve month is 7.7 percent and Profit margin (ttm) is -9.6 Percent. The stock is currently moving above its 20-Day Simple Moving Average of -13.61% with the 50-Day Simple Moving Average of -13.61 percent. Currently, the company has SMA200 (200-day simple moving average) of -47.52 Percent. The Stock has YTD (year to date) performance of -77.22 percent.

Many research firms have provided their ratings on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) where Morgan Stanley provided Overweightrating on the stock on 17-Aug-16. Other firms include Mizuho giving Neutral rating on 15-Aug-16.

In the past 6 months, 6 Insider purchases and 3 Insider Sales were made in which 30775 shares were traded as Insider purchases and 4328940 shares were exchanged as Insider Sales.

Company Profile:

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.